DURHAM, N.C.--(BUSINESS WIRE)--May 31, 2006--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH - News) announced today plans to file an Investigational New Drug (IND) application and begin Phase 2 clinical testing of intranasal epinastine for the treatment of seasonal allergic rhinitis, following the recent completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA).
